Care Capital

Care Capital's deal flow originates primarily from the professional networks of its partners, most of whom held senior R&D or executive roles at large pharmaceutical companies. The firm evaluates academic spinouts, early-stage biotech platforms, and assets that large pharma companies have strategically deprioritized. This network-driven model leverages decades of relationships across academic medical centers, research institutions, and corporate R&D divisions in the US and Europe.

Care Capital focuses on early-stage and growth-stage biopharmaceutical companies, typically leading or co-leading Series A and B financings. The firm's capital is structured to support IND filings, Phase I and Phase II clinical trials, and initial manufacturing scale-up — the translational phase between preclinical validation and regulatory approval. It does not typically invest in seed-stage platform discovery or late-stage pre-commercialization rounds.

The firm's partners — including founder Jan Leschly and other former Merck and SmithKline Beecham executives — evaluate every asset through a clinical-regulatory lens rather than a purely financial one. Investment committee discussions prioritize target-product profiles, clinical-trial design, and FDA pathway feasibility. This operating DNA means the firm often identifies value in scientifically compelling assets that generalist venture investors lack the expertise to diligence.

Yes, the firm's mandate extends to medical devices alongside its core focus on small-molecule therapeutics and biologics. Its partners assess device opportunities with the same regulatory-pathway rigor they apply to drug candidates, though the historical portfolio has weighted more heavily toward pharmaceutical and biologic interventions in CNS, metabolic disease, and oncology.

Care Capital operates as a traditional private equity fund manager with a closed-end fund structure. Its limited partner base has historically included institutional allocators and corporate venture arms from large pharmaceutical companies — a hybrid LP profile that reflects the firm's dual identity as a financial investor and a translational research partner. The firm has not publicly disclosed its total assets under management.

Yes, co-investment with pharmaceutical strategics is a defining feature of Care Capital's model. Major pharma companies — including Johnson & Johnson and Novartis — have co-invested alongside the firm in portfolio companies (per public record). These corporate relationships often extend beyond capital to include development-partnership discussions and eventual acquisition dialogue.

Nearly every investment professional at Care Capital holds an advanced scientific degree or has held R&D leadership roles inside a major pharmaceutical company. This creates an investment committee that reads clinical-trial protocols and regulatory filings with the same fluency a generalist VC would apply to SaaS metrics or consumer cohort analysis. The firm deliberately maintains a lean team — historically six to eight professionals — to preserve this specialist rigor.